AG真人官方

Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc.聽(Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a fireside chat at the Canaccord Genuity 45^th聽Annual Growth Conference taking place from August 12-14, 2025 in Boston, Massachusetts.

Fireside Chat Details:

During the conference, Dr. Vera and Marker鈥檚 management team will conduct one-on-one meetings with registered investors to discuss the Company鈥檚 Multi-Antigen Recognizing (MAR) T cell platform and clinical developments.

To view the event online, investors can register and access the webcast through Marker鈥檚 Investor Relations website under .

About聽Marker Therapeutics, Inc.
Marker Therapeutics, Inc.聽is a聽Houston, TX-based clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors. The Company was founded at聽Baylor College of Medicine, and clinical trials that enrolled more than 200 patients across various hematological and solid tumor indications showed that the Company鈥檚 autologous and allogeneic MAR-T cell products were well tolerated and demonstrated durable clinical responses. Marker鈥檚 goal is to introduce novel T cell therapies to the market and improve patient outcomes. To achieve these objectives, the Company prioritizes the preservation of financial resources and focuses on operational excellence. Marker鈥檚 unique T cell platform is strengthened by non-dilutive funding from聽U.S.聽state and federal agencies supporting cancer research.

To receive future press releases via email, please visit:聽.

Forward-Looking Statements
This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company鈥檚 expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are 鈥渇orward-looking statements.鈥� Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi- antigen recognizing T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; and the timing, conduct, interim results announcements and outcomes of our clinical trials of our product candidates, including MT-601 for the treatment of patients with lymphoma. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company鈥檚 most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at WWW.SEC.GOV. The Company assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release except as may be required by law.

Investor and Media Contact
Marker Therapeutics, Inc.
+1 (713) 400-6400